Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Publikationen des W. G. Kerckhoff-Instituts     Display Documents



ID: 474469.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Publikationen des W. G. Kerckhoff-Instituts
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling
Authors:Schafer, S.; Ellinghaus, P.; Janssen, W.; Kramer, F.; Lustig, K.; Milting, H.; Kast, R.; Klein, M.
Date of Publication (YYYY-MM-DD):2009
Title of Journal:Cardiovasc Res
Volume:82
Issue / Number:1
Start Page:30
End Page:9
Audience:Not Specified
Abstract / Description:AIMS: Inhibition of phosphodiesterase 5 (PDE5) decreases pulmonary pressure and improves symptoms in patients with pulmonary arterial hypertension. It is unclear however, whether inhibition of PDE5 can prevent myocardial remodelling during right-ventricular pressure overload. METHODS AND RESULTS: Right-ventricular pressure overload was produced in male rats in a pulmonary hypertension model (monocrotaline 60 mg/kg s.c.) or by surgical pulmonary artery banding. PDE5 inhibition using oral sildenafil (50 mg/kg/day in drinking water) or placebo was initiated 14 days after monocrotaline treatment and continued for 14 days until final examination. In the pulmonary artery banding groups, rats were treated with sildenafil (50 mg/kg/day) or placebo for 21 days following surgical pulmonary artery banding. At the final experiments, right-ventricular haemodynamics were measured and remodelling was analysed using histological, biochemical, and gene expression markers. Both monocrotaline and pulmonary artery banding increased right-ventricular systolic pressure to approximately 80 mmHg. In parallel, both interventions induced markers of hypertrophy (upregulation of natriuretic peptides, increase in myocyte diameter) and fibrosis (upregulation of collagen types 1A2 and 3A1) as well as mRNA expression of the tissue inhibitor of matrix metalloproteases 1 and osteopontin in the right ventricle. In monocrotaline model, sildenafil decreased pulmonary pressure, reduced right-ventricular hypertrophy, and prevented fibrosis marker gene upregulation. After pulmonary artery banding, in contrast, sildenafil increased markers of myocardial remodelling and right-ventricular myocyte diameter. CONCLUSION: Sildenafil prevents myocardial remodelling in pulmonary hypertension through an indirect action via right-ventricular unloading.
Free Keywords:Administration, Oral; Animals; Blood Pressure/drug effects; Cyclic GMP/blood; Cyclic Nucleotide Phosphodiesterases, Type 5/*antagonists &; inhibitors/metabolism; Disease Models, Animal; Fibrillar Collagens/metabolism; Fibrosis; Hemodynamics/*drug effects; Hypertension, Pulmonary/chemically induced/*drug; therapy/enzymology/physiopathology; Hypertrophy, Right; Ventricular/enzymology/etiology/physiopathology/*prevention & control; Male; Monocrotaline; Myocardium/*enzymology/pathology; Natriuretic Peptides/metabolism; Osteopontin/metabolism; Phosphodiesterase Inhibitors/administration &; dosage/pharmacokinetics/*pharmacology; Piperazines/administration & dosage/pharmacokinetics/*pharmacology; Pulmonary Artery/surgery; Purines/administration & dosage/pharmacokinetics/pharmacology; RNA, Messenger/metabolism; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stroke Volume/drug effects; Sulfones/administration & dosage/pharmacokinetics/*pharmacology; Time Factors; Tissue Inhibitor of Metalloproteinase-1/metabolism; Ventricular Pressure/drug effects; Ventricular Remodeling/*drug effects
External Publication Status:published
Document Type:Article
Communicated by:N. N.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Cardiology Research, Bayer Schering Pharma, Aprather Weg 18, 42096 Wuppertal, Germany.
Identifiers:ISSN:1755-3245 (Electronic) 0008-6363 (Linking)
URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=..
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.